WHAT IS CLAIMED IS:

~~1.~~ An antibody that binds to a GARP/TGFβ complex comprising:

~~a) a heavy chain variable region comprising:~~

~~(1) a heavy chain variable region CDR-H1 comprising an amino acid sequence of any one of SEQ ID NOs: 1, 11, 21, 31, 41, 51, 61 and 105, or a variant thereof comprising up to about 3 amino acid substitutions;~~

~~(2) a heavy chain variable region CDR-H2 comprising an amino acid sequence of any one of SEQ ID NOs: 2, 12, 22, 32, 42, 52, 62 and 106, or a variant thereof comprising up to about 3 amino acid substitutions; and~~

~~(3) a heavy chain variable region CDR-H3 comprising an amino acid sequence of any one of SEQ ID NOs: 3, 13, 23, 33, 43, 53, 63 and 107, or a variant thereof comprising up to about 3 amino acid substitutions; and~~

~~b) a light chain variable region comprising:~~

~~(1) a light chain variable region CDR-L1 comprising an amino acid sequence of any one of SEQ ID NOs: 4, 14, 24, 34, 44, 54, 64 and 108, or a variant thereof comprising up to about 3 amino acid substitutions;~~

~~(2) a light chain variable region CDR-L2 comprising an amino acid sequence of any one of SEQ ID NOs: 5, 15, 25, 35, 45, 55, 65 and 109, or a variant thereof comprising up to about 3 amino acid substitutions; and~~

~~(3) a light chain variable region CDR-L3 comprising an amino acid sequence of any one of SEQ ID NOs: 6, 16, 26, 36, 46, 56, 66 and 110, or a variant thereof comprising up to about 3 amino acid substitutions.~~

~~2. The antibody of claim 1, wherein the antibody binds to GARP/TGFβ complex with a KD of $1x10^{-7}$ M or less.~~

~~3. The antibody of claim 1 or 2, wherein the antibody binds to GARP/TGFβ complex with a KD of $1x10^{-8}$ M or less.~~

~~4. The antibody of any one of claims 1-3, wherein antibody binds to GARP/TGFβ complex with a KD of between about $1x10^{-11}$ M and about $1x10^{-7}$ M.~~

~~5. The antibody of any one of claims 1-4, wherein the antibody binds to GARP/TGFβ complex with a KD of between about $1x10^{-10}$ M and about $5x10^{-8}$ M.~~

~~6.~~1. ~~The antibody of any one of claims 1-5, wherein the antibody cross-competes with a reference anti-GARP/TGFβ antibody comprising:~~

- a) a heavy chain variable domain (VH) sequence comprising (1) a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 1, (2) a CDR- H2 comprising the amino acid sequence set forth in SEQ ID NO: 2, and (3) a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 3; and a light chain variable domain (VL) sequence comprising (1) a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 4, (2) a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 5, and (3) a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 6;

b) a heavy chain variable domain (VH) sequence comprising (1) a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 11, (2) a CDR- H2 comprising the amino acid sequence set forth in SEQ ID NO: 12, and (3) a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 13; and a light chain variable domain (VL) sequence comprising (1) a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 14, (2) a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 15, and (3) a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 16;

c) a heavy chain variable domain (VH) sequence comprising (1) a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 21, (2) a CDR- H2 comprising the amino acid sequence set forth in SEQ ID NO: 22, and (3) a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 23; and a light chain variable domain (VL) sequence comprising (1) a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 24, (2) a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 25, and (3) a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 26;

d) a heavy chain variable domain (VH) sequence comprising (1) a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 31, (2) a CDR- H2 comprising the amino acid sequence set forth in SEQ ID NO: 32, and (3) a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 33; and a light chain variable domain (VL) sequence comprising (1) a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 34, (2) a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 35, and (3) a CDR-L3 comprising

the amino acid sequence set forth in SEQ ID NO: 36;

e) a heavy chain variable domain (VH) sequence comprising (1) a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 41, (2) a CDR- H2 comprising the amino acid sequence set forth in SEQ ID NO: 42, and (3) a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 43; and a light chain variable domain (VL) sequence comprising (1) a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 44, (2) a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 45, and (3) a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 46;

f) a heavy chain variable domain (VH) sequence comprising (1) a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 51, (2) a CDR- H2 comprising the amino acid sequence set forth in SEQ ID NO: 52, and (3) a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 53; and a light chain variable domain (VL) sequence comprising (1) a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 54, (2) a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 55, and (3) a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 56;

g) a heavy chain variable domain (VH) sequence comprising (1) a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 61, (2) a CDR- H2 comprising the amino acid sequence set forth in SEQ ID NO: 62, and (3) a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 63; and a light chain variable domain (VL) sequence comprising (1) a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 64, (2) a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 65, and (3) a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 66; or

h) a heavy chain variable domain (VH) sequence comprising (1) a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 105, (2) a CDR- H2 comprising the amino acid sequence set forth in SEQ ID NO: 106, and (3) a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 107; and a light chain variable domain (VL) sequence comprising (1) a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 108, (2) a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 109, and (3) a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 110.

~~7. The antibody of any one of claims 1-6, wherein the antibody comprises:~~

~~a) a heavy chain variable region that comprises a CDR-H1 domain, a CDR-H2 domain~~

and a CDR-H3 domain, wherein the CDR-H1 domain, the CDR-H2 domain and the CDR-H3 domain respectively comprise a CDR-H1 domain, a CDR-H2 domain and a CDR-H3 domain comprised in a reference heavy chain variable region comprising the amino acid sequence selected from the group consisting of SEQ ID NOs: 7, 17, 27, 37, 47, 57, 67, 85, 89, 93, 97, 101 and 111; and

b) a light chain variable region that comprises a CDR-L1 domain, a CDR-L2 domain and a CDR-L3 domain, wherein the CDR-L1 domain, the CDR-L2 domain and the CDR-L3 domain respectively comprise a CDR-L1 domain, a CDR-L2 domain and a CDR-L3 domain comprised in a reference light chain variable region comprising the amino acid sequence selected from the group consisting of SEQ ID NOs: 8, 18, 28, 38, 48, 58, 68, 83, 84, 86, 90, 94, 98, 102 and 112.

8. The antibody of any one of claims 1-7, wherein the antibody comprises a heavy chain variable domain (VH) sequence comprising (1) a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 1, (2) a CDR- H2 comprising the amino acid sequence set forth in SEQ ID NO: 2, and (3) a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 3; and a light chain variable domain (VL) sequence comprising (1) a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 4, (2) a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 5, and (3) a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 6.

9. The antibody of any one of claims 1-7, wherein the antibody comprises a heavy chain variable domain (VH) sequence comprising (1) a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 11, (2) a CDR- H2 comprising the amino acid sequence set forth in SEQ ID NO: 12, and (3) a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 13; and a light chain variable domain (VL) sequence comprising (1) a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 14, (2) a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 15, and (3) a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 16.

10. The antibody of any one of claims 1-7, wherein the antibody comprises a heavy chain variable domain (VH) sequence comprising (1) a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 21, (2) a CDR- H2 comprising the amino acid sequence set forth in SEQ

~~ID NO: 22, and (3) a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 23; and a light chain variable domain (VL) sequence comprising (1) a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 24, (2) a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 25, and (3) a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 26.~~

~~11. The antibody of any one of claims 1-7, wherein the antibody comprises a heavy chain variable domain (VH) sequence comprising (1) a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 31, (2) a CDR- H2 comprising the amino acid sequence set forth in SEQ ID NO: 32, and (3) a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 33; and a light chain variable domain (VL) sequence comprising (1) a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 34, (2) a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 35, and (3) a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 36.~~

~~12.~~2. The antibody of ~~any one of~~ claim~~s~~ 1~~-7~~, wherein the antibody comprises a heavy chain variable domain (VH) sequence comprising (1) a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 41, (2) a CDR- H2 comprising the amino acid sequence set forth in SEQ ID NO: 42, and (3) a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 43; and a light chain variable domain (VL) sequence comprising (1) a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 44, (2) a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 45, and (3) a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 46.

~~13. The antibody of any one of claims 1-7, wherein the antibody comprises a heavy chain variable domain (VH) sequence comprising (1) a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 51, (2) a CDR- H2 comprising the amino acid sequence set forth in SEQ ID NO: 52, and (3) a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 53; and a light chain variable domain (VL) sequence comprising (1) a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 54, (2) a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 55, and (3) a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 56.~~

~~14. The antibody of any one of claims 1-7, wherein the antibody comprises a heavy chain variable domain (VH) sequence comprising (1) a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 61, (2) a CDR- H2 comprising the amino acid sequence set forth in SEQ ID NO: 62, and (3) a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 63; and a light chain variable domain (VL) sequence comprising (1) a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 64, (2) a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 65, and (3) a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 66.~~

~~15.~~3. The antibody of ~~any one of~~ claim~~s~~ 1~~-7~~, wherein the antibody comprises a heavy chain variable domain (VH) sequence comprising (1) a CDR-H1 comprising the amino acid sequence set forth in SEQ ID NO: 105, (2) a CDR- H2 comprising the amino acid sequence set forth in SEQ ID NO: 106, and (3) a CDR-H3 comprising the amino acid sequence set forth in SEQ ID NO: 107; and a light chain variable domain (VL) sequence comprising (1) a CDR-L1 comprising the amino acid sequence set forth in SEQ ID NO: 108, (2) a CDR-L2 comprising the amino acid sequence set forth in SEQ ID NO: 109, and (3) a CDR-L3 comprising the amino acid sequence set forth in SEQ ID NO: 110.

~~16.~~ The antibody of any one of claims 1~~-15~~3, wherein the antibody comprises:

a) ~~-~~a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 7, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 8~~.~~;

~~17. The antibody of any one of claims 1-15,~~

b) ~~wherein the antibody comprises~~ a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 17, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 18;

c) ~~.~~

~~18. The antibody of any one of claims 1-15, wherein the antibody comprises~~ a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 27, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 28;

d) ~~.~~

~~19. The antibody of any one of claims 1-15, wherein the antibody comprises~~ a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 37, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 38;

e) ~~.~~

~~20. The antibody of any one of claims 1-15, wherein the antibody comprises~~ a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 37, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 83;

f) ~~.~~

~~21. The antibody of any one of claims 1-15, wherein the antibody comprises~~ a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 47, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 48;

g) ~~.~~

~~22. The antibody of any one of claims 1-15, wherein the antibody comprises~~ a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 47, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 84;

h) ~~.~~

~~23. The antibody of any one of claims 1-15, wherein the antibody comprises~~ a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 57, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 58;

i) ~~.~~

~~24. The antibody of any one of claims 1-15, wherein the antibody comprises~~ a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 67, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 68;

j) ~~.~~

~~25. The antibody of any one of claims 1-15, wherein the antibody comprises~~ a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 85, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 86;

k) ~~.~~

~~26. The antibody of any one of claims 1-15, wherein the antibody comprises~~ a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 89, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 90;

l) ~~.~~

~~27. The antibody of any one of claims 1-15, wherein the antibody comprises~~ a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 93, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 94;

m) ~~.~~

~~28. The antibody of any one of claims 1-15, wherein the antibody comprises~~ a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 97, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 98;

n) ~~.~~

~~29. The antibody of any one of claims 1-15, wherein the antibody comprises~~ a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 101, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 102; or

o) ~~.~~

4. ~~The antibody of any one of claims 1-15, wherein the antibody comprises~~ a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 111, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 112.

5. The antibody of any one of claims 1-4, wherein the antibody comprises a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 85, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 86.

~~30.~~6. The antibody of any one of claims 1-4, wherein the antibody comprises a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 111, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 112.

~~31. The antibody of any one of claims 1-30, wherein the antibody comprises a human framework.~~

~~32. The antibody of any one of claims 1-31, wherein the antibody is a human antibody.~~

~~33. The antibody of any one of claims 1-31, wherein the antibody is a humanizedantibody.~~

~~34.~~7. The antibody of any one of claims 1-~~33~~6, wherein the antibody comprises a full-length immunoglobulin, a single-chain Fv (scFv) fragment, a Fab fragment, a Fab' fragment, a F(ab')2, a Fv fragment, a disulfide stabilized Fv fragment (dsFv), a (dsFv)2, a Fv-Fc fusion, a scFv-Fc fusion, a scFv-Fv fusion, a diabody, a tribody, a tetrabody or any combination thereof.

~~35.~~8. The antibody of any one of claims 1-~~34~~7**,** wherein the antibody comprises a Fc region.

~~36. The antibody of any one of claims 1-35, wherein the Fc region comprises a human Fc region.~~

~~37. The antibody of any one of claims 1-36, wherein the Fc region comprises a Fc region selected from the group consisting of the Fc regions of IgG, IgA, IgD, IgE and IgM.~~

~~38.~~9. The antibody of ~~any one of~~ claim~~s 1-37~~ 8, wherein the Fc region comprises a Fc region selected from the group consisting of the Fc regions of IgG1, IgG2, IgG3 and IgG4.

~~39.~~ The antibody of ~~any one of~~ claim~~s 1-38~~ 8 or 9, wherein the Fc region comprises an IgG1 Fc region ~~.~~

~~40.~~10. ~~The antibody of any one of claims 1-38, wherein the Fc region comprises~~or an IgG4 Fc region.

~~41. The antibody of any one of claims 1-40, wherein theantibody binds to human GARP/TGFβ complex.~~

~~42. The antibody of any one of claims 1-41, wherein theantibody binds to cynomolgus GARP/TGFβ complex.~~

~~43. The antibody of any one of claims 1-42, wherein theantibody binds to human GARP/TGFβ complex, cynomolgus GARP/TGFβ complex and mouse GARP/TGFβ complex.~~

~~44.~~11. The antibody of any one of claims ~~1~~8-~~43~~10, wherein the Fc region comprises a C-

terminal lysine.

~~45.~~12. The antibody of any one of claims ~~1~~8-~~43~~10, wherein the Fc region comprises a deletion of a C-terminal lysine.

~~46. The antibody of any one of claims 1-45, wherein the antibody is comprised in a multispecific antibody, e.g., a bispecific antibody, wherein the multispecific antibody comprises a second antibody moiety that specifically binds to a second antigen.~~

~~47. The antibody of claim 46, wherein the second antigen is a tumor associated antigen.~~

~~48. The antibody of claim 47, wherein the tumor associated antigen is selected from the group consisting of Her-2, EGFR, PDL1, MSLN, c-Met, B Cell Maturation Antigen (BCMA), carbonic anhydrase IX (CA1X), carcinoembryonic antigen (CEA), CD5, CD7, CD10, CD19, CD20, CD22, CD30, CD33, CD34, CD38, CD41, CD44, CD47, CD49f, CD56, CD74, CD123, CD133, CD138, CD276 (B7H3), epithelial glycoprotein (EGP2), trophoblast cell-surface antigen 2 (TROP-2), epithelial glycoprotein- 40 (EGP-40), epithelial cell adhesion molecule (EpCAM), receptor tyrosine-protein kinases erb-B2,3,4, folate-binding protein (FBP), fetal acetylcholine receptor (AChR), folate receptor-a, Ganglioside G2 (GD2), Ganglioside G3 (GD3), human telomerase reverse transcriptase (hTERT), kinase insert domain receptor (KDR), Lewis A (CA 1.9.9), Lewis Y (LeY), Glypican-3 (GPC3), L1-cell adhesion molecule (L1CAM), Mucin 16 (Muc-16), Mucin 1 (Muc-1), NG2D ligands, oncofetal antigen (h5T4), prostate stem cell antigen (PSCA), prostate-specific membrane antigen (PSMA), tumor- associated glycoprotein 72 (TAG-72), Claudin18.2 (CLDN18.2), vascular endothelial growth factor R2 (VEGF- R2), Wilms tumor protein (WT-1), type-1 tyrosine-protein kinase transmembrane receptor (ROR1), PVR, PVRL2, and any combination thereof.~~

~~49. The antibody of claim 48, wherein the second antigen is an immune checkpoint regulator.~~

~~50. The antibody of claim 49, wherein the immune checkpoint regulator is selected from the group consisting of TIGIT, PD1, CTLA4, LAG-3, 2B4, BTLA and any combination thereof.~~

~~51. The antibody of claim 48, wherein the second antigen is an immune costimulatorymolecule or a subunit of a T-cell receptor/CD3 complex.~~

~~52. The antibody of claim 51, wherein the immune costimulatory molecule is selected from the group consisting of CD28, ICOS, CD27, 4-1BB, OX40 and CD40 and any combination thereof.~~

~~53. The antibody of claim 51, wherein the subunit of the T cell receptor/CD3 complex is selected from the group consisting of CD3γ, CD3δ, CD3ε and any combination thereof.~~

~~54.~~13. An immunoconjugate comprising the antibody of any one of claims 1-~~53~~12, linked to a therapeutic agent or a label.

~~55.~~14. The immunoconjugate of claim ~~54~~13, wherein the therapeutic agent is a cytotoxin or a radioactive isotope.

~~56.~~15. The immunoconjugate of claim ~~54~~14, wherein the label is selected from the group consisting of a radioisotope, a fluorescent dye and an enzyme.

~~57.~~16. An antigen-recognizing receptor comprising an extracellular antigen-binding domain that comprises an antibody of any one of claims 1-~~53~~12.

~~58. The~~ The antigen-recognizing receptor of claim ~~57~~16, which is a Chimeric Antigen Receptor (CAR) ~~or a recombinant T cell Receptor.~~

~~59.~~17. ~~The antigen-recognizing receptor of claim 57 or 58, which is a CAR~~.

~~60.~~18. The antigen-recognizing receptor of ~~any one of~~ claim~~s57-59~~ 16 or 17, wherein the antibody is a scFv ~~or a Fab~~.

~~61.~~19. An immunoresponsive cell comprising an antigen-recognizing receptor of any one of claims~~57~~16-~~60~~18.

~~62.~~20. The immunoresponsive cell of claim ~~61~~19, wherein the immunoresponsive cell is selected from the group consisting of a T cell, a Natural Killer (NK) cell, a cytotoxic T lymphocyte (CTL), a regulatory T cell, a Natural Killer T (NKT) cell and a myeloid cell.

~~63.~~21. The immunoresponsive cell of claim ~~62~~20, wherein the immunoresponsive cell is a T cell.

~~64.~~22. A pharmaceutical composition comprising a) the antibody of any one of claims 1-~~53~~12, the immunoconjugate of any one of claims ~~54~~13-~~56~~15, or the immunoresponsive cell of any one of claims ~~61~~19-~~63~~21, and b) a pharmaceutically acceptable carrier.

~~65.~~23. One or more nucleic acid encoding the antibody of any one of claims 1-~~53~~12.

~~66.~~24. One or more vector comprising the nucleic acid of claim ~~65~~23.

~~67.~~25. A host cell comprising the nucleic acid of claim ~~65~~-23 or the vector of claim ~~66~~24.

~~68.~~26. A method for preparing an antibody of any one of claims 1-~~53~~12 comprising expressing the antibody in the host cell of claim ~~67~~25 and isolating the antibody from the host cell.

~~69. A method of reducing tumor burden in a subject, the method comprising administering to the subject an effective amount of an antibody of any one of claims 1-53, an immunoconjugate of any one of claims 54-56, or a pharmaceutical composition of claim 64.~~

~~70. The method of claim 69, wherein the method reduces the number of tumor cells.~~

~~71. The method of claim 69or 70, wherein the method reduces tumor size.~~

~~72. The method of any one of claims 69-71, wherein the method eradicates the tumor in the subject.~~

~~73. The method of any one of claims 69-72, wherein the tumor exhibits high microsatellite instability (MSI).~~

~~74. The method of any one of claims 69-73, wherein the tumor is selected from the group consisting of mesothelioma, lung cancer, pancreatic cancer, ovarian cancer, breast cancer, colon cancer, pleural tumor, glioblastoma, esophageal cancer, gastric cancer, synovial sarcoma, thymic carcinoma, endometrial carcinoma, stomach cancer, cholangiocarcinoma, head and neck cancer, blood cancer and a combination thereof.~~

~~75. A method of treating and/or preventing cancer, the method comprising administering to the subject an effective amount of an antibody of any one of claims 1-53, an immunoconjugate of any one of claims 53-56, or a pharmaceutical composition of claim 64.~~

~~76. A method of lengthening survival of a subject having cancer, the method comprising administering to the subject an effective amount of an antibody of any one of claims 1-63, an immunoconjugate of any one of claims 54-56, or a pharmaceutical composition of claim 64.~~

~~77. The method of claim 75 or 76, wherein the cancer exhibits high microsatellite instability (MSI).~~

~~78. The method of any one of claims75-77, wherein the cancer is selected from the group consisting of mesothelioma, lung cancer, pancreatic cancer, ovarian cancer, breast cancer, colon cancer, pleural tumor, glioblastoma, esophageal cancer, gastric cancer, synovial sarcoma, thymic carcinoma, endometrial carcinoma, stomach cancer, cholangiocarcinoma, head and neck cancer, blood cancer and a combination thereof.~~

~~79.~~27. An antibody of any one of claims 1-~~53~~12 for use as a medicament.

~~80.~~28. An antibody of any one of claims 1-~~53~~12 for use in treating cancer.

~~81.~~29. A pharmaceutical composition of claim ~~64~~22 for use as a medicament.

~~82.~~30. A pharmaceutical composition of claim ~~64~~22 for use in treating cancer.

~~83.~~31. The antibody of claim ~~86~~28 or the pharmaceutical composition of claim ~~82~~30, wherein the cancer exhibits high microsatellite instability (MSI).

~~84.~~32. The antibody of claim ~~80~~28 or the pharmaceutical composition of claim ~~82~~30, wherein the cancer is selected from the group consisting of mesothelioma, lung cancer, pancreatic cancer, ovarian cancer, breast cancer, colon cancer, pleural tumor, glioblastoma, esophageal cancer, gastric cancer, synovial sarcoma, thymic carcinoma, endometrial carcinoma, stomach cancer, cholangiocarcinoma, head and neck cancer, blood cancer and a combination thereof.

~~85.~~33. A kit comprising an antibody of any one of claims 1-~~53~~12, an immunoconjugate of any one of claims ~~54~~13-~~56~~15, a pharmaceutical composition of claim ~~64~~22, a nucleic acid of claim ~~65~~23, a vector of claim ~~66~~24 or an immunoresponsive cell of claim ~~61~~19-~~63~~21.

~~86.~~34. The kit of claim ~~85~~33, further comprising a written instruction for treating and/or

preventing a neoplasm.

~~87.~~35. ~~A method of treating cancer in a subject comprising administering to the subject an effective amount of a~~n anti-GARP/TGFβ antibody and an anti-PD1 antibody for use in treating cancer.

~~88.~~36. The anti-GARP/TGFβ antibody and the anti-PD1 antibody~~method~~ of claim ~~87~~35, wherein the anti-GARP/TGFβ antibody is an anti-GARP/TGFβ antibody of any one of claims 1-~~53~~12.

~~89.~~37. The anti-GARP/TGFβ antibody and the anti-PD1 antibody~~method~~ of claim ~~87~~ 35 or ~~88~~36, wherein the cancer exhibits high microsatellite instability (MSI).

~~90.~~38. The anti-GARP/TGFβ antibody and the anti-PD1 antibody~~method~~ of any one of claims ~~87~~35-~~89~~37, wherein the cancer is selected from the group consisting of mesothelioma, lung cancer, pancreatic cancer, ovarian cancer, breast cancer, colon cancer, pleural tumor, glioblastoma, esophageal cancer, gastric cancer, synovial sarcoma, thymic carcinoma, endometrial carcinoma, stomach cancer, cholangiocarcinoma, head and neck cancer, blood cancer and a combination thereof.

~~91. The method of any one of claims 87-90, wherein the anti-GARP/TGFβ antibody and the anti-PD1 antibody are administered concurrently or sequentially.~~

~~92. The method of any one of claims 87-91, wherein the anti-GARP/TGFβ antibody and the anti-PD1 antibody are administered concurrently.~~

~~93. The method of any one of claims 87-92, wherein one or more doses of the anti-PD1 antibodyis administered prior to administering the anti-GARP/TGFβ antibody.~~

~~94. The method of any one of claims 87-93, wherein the subject received a complete course of the anti-PD1 antibody therapy prior to administration of the anti-GARP/TGFβ antibody.~~

~~95. The method of any one of claims 87-94, wherein the anti-GARP/TGFβ antibody is administered during a second course of the anti-PD1 antibody therapy.~~

~~96. The method of any one of claims 87-95, wherein the subject received at least one, at least two, at least three, or at least four doses of the anti-PD1 antibody prior to administration of the anti-GARP/TGFβ antibody.~~

~~97. The method of any one of claims 87-96, wherein at least one dose of the anti-PD1 antibody is administered concurrently with the anti-GARP/TGFβ antibody.~~

~~98. The method of any one of claims 87-97, wherein one or more doses of the anti-GARP/TGFβ antibody are administered prior to administering the anti-PD1 antibody.~~

~~99. The method of any one of claims 87-98, wherein the subject received at least two, at least three, at least three, or at least four doses of the anti-GARP/TGFβ antibody prior to administration of the anti-PD1 antibody.~~

~~100. The method of any one of claims 87-99, wherein at least one dose of the anti-GARP/TGFβ antibody is administered concurrently with the anti-PD1 antibody.~~

~~101. The method of any one of claims 87-100, wherein the anti-GARP/TGFβ antibody and the anti-PD1 antibody are administered once every 1, 2, 3, 4, or 5 weeks.~~

~~102. The method of any one of claims 87-101, wherein the cancer is recurrent or progressive after a therapy selected from the group consisting of surgery, chemotherapy, radiation therapy and any combination thereof.~~